ClinicalTrials.gg

TargetBeta

FGFR2

fibroblast growth factor receptor 2 · also CEK3, TK14, TK25, ECT1 · CD molecules

8 programs in company-led studies act on FGFR2, from 8 companies: 3 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
regorafenibruleBayerphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
nintedanibruleBoehringer Ingelheimphase 4761 runningFGFR1, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRBChEMBL
futibatinibruleOtsukaphase 3104 runningFGFR1, FGFR3, FGFR4ChEMBL
infigratinibruleBridgeBiophase 3173 runningFGFR1, FGFR3, FGFR4ChEMBL
pemigatinibruleIncytephase 3161 runningFGFR1, FGFR3ChEMBL
lirafugratinibruleElevar Therapeuticsphase 221 running–NCIt
FGFR2/3 Inhibitor CGT4859ruleCogent Biosciencesphase 211 running–NCIt
KNT-0916ruleKinoTeck Therapeuticsphase 111 running–the studies' text

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.